Original Publication Date: 8 February, 2016
Publication / Source: Breast Cancer Management
Authors: Jafri M & Rea D
A long established oncological dogma requires that trastuzumab should not be given in combination with anthracyclines due to excessive synergistic cardiac morbidity. However, trastuzumab has been recently granted a license in the neoadjuvant setting with concurrent anthracylines. We discuss the role of anti-HER2 agents in breast cancer and their associated toxicities. Anthracycline chemotherapies are a central component of most adjuvant and neoadjuvant breast cancer regimens. Cardiac toxicity due to anthracyclines is explored. Finally, in this article, we will discuss the evidence for concurrent administration of anthracyclines and HER2-targeted agents.
Since the pivotal trial describing the use of trastuzumab in metastatic HER2-positive breast cancer 14 years ago , many oncologists have had significant concerns regarding the association of anti-HER2-targeted therapies with cardiac toxicity. The risk of toxicity was striking in patients who had received concurrent doxorubicin with trastuzumab. In the adjuvant studies of trastuzumab, sequential anthracyclines and trastuzumab were used [2,3].